Weaver Consulting Group Gilead Sciences, Inc. Transaction History

Weaver Consulting Group

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 29, 2021	SELL	$56.65 - $64.55 $63,448 - $72,296	-1,120 Closed	0 $0
Q3 2020 Oct 28, 2020	SELL	$62.1 - $78.08 $9,936 - $12,492	-160 Reduced 12.5%	1,120 $71,000
Q2 2020 Jul 24, 2020	BUY	$72.34 - $84.0 $3,978 - $4,620	55 Added 4.49%	1,280 $99,000
Q1 2020 Apr 28, 2020	BUY	$62.63 - $80.22 $44,216 - $56,635	706 Added 136.03%	1,225 $92,000
Q1 2019 Jun 19, 2019	BUY	$62.53 - $70.05 $32,453 - $36,355	519 New	519 $34,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Weaver Consulting Group, based on Form 13F filings with the SEC.

Stay updated on Weaver Consulting Group with notifications on news.